Cargando…
SUN-LB024 Elevation in Morning Glucose Level May Be a Signal for the Development of Immune Checkpoint Inhibitor (ICPi) Induced Autoimmune Diabetes Insulin
Unleashing the immune system by using immune checkpoint inhibitors (ICPi) has become a powerful tool in treating a broad spectrum of malignancies. However, increasing the immune response through ICPi therapy can also induce immune-related adverse effects (irAEs). Autoimmune diabetes is a significant...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553107/ http://dx.doi.org/10.1210/js.2019-SUN-LB024 |